Table 2

Prevalence of MTX-related gastrointestinal symptoms in all patients and in intolerant patients by route of MTX administration
All patients Tolerant to MTX Intolerant to MTX Oral MTX Parenteral MTX
Total 291 (100) 259 (89.0) 32 (11.0) 194 (66.7) 97 (33.3)
Cutoff score ≥6 32 (11.0) 0 (0) 32 (100) 12 (6.2) 20 (20.6)a
Abdominal pain 44 (15.1) 24 (9.3) 20 (62.5) 7 (58.3) 13 (65.0)
   After MTX 33 (11.3) 18 (6.9) 15 (46.9) 5 (41.7) 10 (50.0)
   Anticipatory 17 (5.8) 5 (1.9) 12 (37.5) 5 (41.7) 7 (35.0)
   Associative 17 (5.8) 6 (2.3) 11 (34.4) 4 (33.3) 7 (35.0)
Nausea 100 (34.4) 68 (26.3) 32 (100) 12 (100) 20 (100)
   After MTX 93 (32.0) 61 (23.6) 32 (100) 12 (100) 20 (100)
   Anticipatory 25 (8.6) 7 (2.7) 18 (56.3) 6 (50.0) 12 (60.0)
   Associative 32 (11.0) 15 (5.8) 17 (53.1) 5 (41.7) 12 (60.0)
Vomiting 22 (7.6) 11 (4.2) 11 (34.4) 5 (41.7) 6 (30.0)
   After MTX 19 (6.5) 9 (3.5) 10 (31.3) 5 (41.7) 5 (25.0)
   Anticipatory 5 (1.7) 0 (0) 5 (15.6) 2 (16.7) 3 (15.0)
Behavioural symptoms 48 (16.5) 22 (8.5) 26 (81.3) 7 (58.3) 19 (95.0)b
   Restlessness 38 (13.1) 16 (6.2) 22 (68.8) 6 (50.0) 16 (80)
   Irritability 29 (10.0) 7 (2.7) 22 (68.8) 5 (41.7) 17 (85.0)c
   Refusal of MTX 13 (4.5) 1 (0.4) 12 (37.5) 2 (16.7) 10 (50.0)

Values are number (%) of patients. All domains and individual items differentiate between tolerant and intolerant patients (P < 0.001). aP < 0.001 versus oral MTX, by chi-square test; bP = 0.02 versus oral MTX, by chi-square test, cP = 0.02 versus oral MTX, by chi-square test. MTX, methotrexate.

Bulatović Ćalasan et al.

Bulatović Ćalasan et al. Arthritis Research & Therapy 2013 15:R217   doi:10.1186/ar4413

Open Data